In vitro experiments have demonstrated that the novel combination of vitexin and aspirin has some synergistic enhancement against colorectal cancer, and the mechanism may be the inhibition of NFKB1 activity, thus inhibiting the expression of COX-2, which in turn inhibits the proliferation of colorectal cancer cells. Here, NFKB1 is linked to colorectal cancer.